ĐẶC ĐIỂM LÂM SÀNG, XÉT NGHIỆM BỆNH NHÂN NGHI NGỜ GIẢM TIỂU CẦU HUYẾT KHỐI SAU TIÊM VACXIN PHÒNG COVID 19 TẠI BỆNH VIỆN BẠCH MAI

Abstract

Objective: to describe clinical and laboratory findings of vitt suspected patients. Subjects and methods: Cross-sectional descriptive study of 35 patients who were clinical suspicious of VITT at Bach Mai Hospital in 2021. Results: Mean age is 42.63 ± 17.21, with female patients accounted for 63%. Patients immunized with adenovirus based vaccines accounted for 85.7%; mean duration from vaccination to onset of clinical symptoms was 8.38 ± 6.68 days. Primary symptoms were headache (37%), internal hemorrhage, thrombosis (42.9%) of which the most prevelant sites were cerebral sinus veins (60%). Laboratory findings: 14.3% of patients were HPIA positive; 57% experienced thrombocytopenia; mean level of D-Dimer was 12.29 ± 37.12 mg/l FEU. The age of patients with a positive HPIA test is statistically significant lower than the negative group, the mean Ddimer concentration, the rate of thrombosis, the location of thrombosis of patients with a positive HPIA test is higher than that of the negative group with a positive HPIA test. Conclusion: VITT is a serious complication after the adenovirus vaccine against covid 19. Recognizing the typical symptoms of VITT helps doctors diagnose and treat patients promptly.